Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ganesh Raghu. Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017

Member's Comments

No comment yet.

Related content which might interest you: Idiopathic pulmonary fibrosis: present understanding and future options Source: Eur Respir Rev 2011; 20: 132-133 Year: 2011 Idiopathic pulmonary fibrosis: current challenges and future perspectives Source: Eur Respir Rev 2013; 22: 103-105 Year: 2013 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 The changing treatment landscape in idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 65-68 Year: 2015 A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials Source: Eur Respir J 2015; 46: 243-249 Year: 2015 Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013 The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF Source: Eur Respir J 2015; 46: 883-886 Year: 2015 Staging of idiopathic pulmonary fibrosis: past, present and future Source: Eur Respir Rev 2014; 23:220-224 Year: 2014 Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1218-1220 Year: 2015 The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019 Idiopathic pulmonary fibrosis: recent milestones in disease management Source: Eur Respir Rev 2012; 21: 140 Year: 2012 Historical eye on idiopathic pulmonary fibrosis: redefining the mortality scenario. Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis Year: 2020 Idiopathic pulmonary fibrosis: another step in understanding the burden of this disease Source: Eur Respir J 2016; 48: 26-28 Year: 2016 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches Source: Eur Respir J 2006; 28: 463-465 Year: 2006 Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions Source: Eur Respir Rev, 27 (147) 170076; 10.1183/16000617.0076-2017 Year: 2018 Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science Source: Eur Respir J 2016; 47:1615-1617 Year: 2016